Optinose Named a 2019 Best Place to Work by Philadelphia Business Journal
19 juin 2019 16h30 HE
|
Optinose, Inc.
YARDLEY, Pa., June 19, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports First Quarter 2019 Financial Results and Recent Operational Highlights
09 mai 2019 07h00 HE
|
Optinose, Inc.
Company reports first quarter 2019 total revenues of $4.5 million. XHANCE first quarter net product revenues grew to $4.0 million XHANCE prescriptions increased 59% from fourth quarter 2018 to first...
Optinose to Report First Quarter 2019 Financial Results and Corporate Updates on May 9, 2019
25 avr. 2019 07h00 HE
|
Optinose, Inc.
YARDLEY, Pa., April 25, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Highlights
06 mars 2019 07h00 HE
|
Optinose, Inc.
Company reports fourth quarter and full year 2018 net XHANCE revenue of $3.0 million and $7.1 million XHANCE prescriptions increased 50 percent from Q3 to Q4 of 2018 Conference call and webcast to...
Optinose to Report Fourth Quarter 2018 Financial Results and Corporate Updates on March 6, 2019
27 févr. 2019 07h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Issuance of Four Additional U.S. Patents Covering XHANCE
19 févr. 2019 07h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Highlight Data at the 2019 AAAAI Annual Meeting in San Francisco
15 févr. 2019 07h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces License Agreement
04 févr. 2019 07h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and...
Optinose Announces Update to License Agreement with Avanir Pharmaceuticals for ONZETRA XSAIL
11 déc. 2018 07h00 HE
|
OptiNose, Inc.
YARDLEY, Pa., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces First Patient Enrolled in Clinical Trial of XHANCE for Chronic Sinusitis
10 déc. 2018 07h00 HE
|
OptiNose, Inc.
YARDLEY, Pa., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, announced today...